Minnesota | 41-1424202 |
State or other jurisdiction of incorporation or organization | (I.R.S.Employer Identification No.) |
11409 Valley View Road, Eden Prairie, Minnesota | 55344 |
(Address of principal executive offices) | (Zip Code) |
Title
of each class
|
Name of each exchange on which registered
|
Common stock, $0.01 par value (Common Stock)
|
The NASDAQ Stock Market, LLC
|
Large accelerated filer [ ] | Accelerated filer [X] |
Non-accelerated filer [ ] (Do not check if a smaller reporting company) | Smaller reporting company [ ] |
| current sensors for energy management; | |
| high isolation-voltage couplers for smart-grid and medical instrument applications; and | |
| quarter-size data couplers and network couplers. |
| new sensors for medical devices; | |
| biosensors for food safety and medical diagnostics; | |
| low-power couplers; and | |
| antitamper sensors. |
| technological innovations by us or our competitors; | |
| the announcement of new products, product enhancements, contracts, or license agreements by us or our competitors; | |
| delays in our introduction of new products or technologies or market acceptance of these products or technologies; | |
| loss of customers, decreases in customer purchases, or decreases in customers purchase prices; | |
| changes in demand for our customers products; | |
| quarterly variations in our operating results, revenue, or revenue growth rates; | |
| changes in revenue estimates, earnings estimates, or market projections by market analysts; | |
| speculation in the press or analyst community about our business, potential revenue, or potential earnings; | |
| general economic conditions or market conditions specific to industries we or our customers serve or may serve; | |
| legal proceedings involving us, including intellectual property litigation or class action litigation; and | |
| our stock repurchase and dividend policies and decisions. |
Quarter Ended | |||||||||||||||||||||||
3/31/15 | 12/31/14 | 9/30/14 | 6/30/14 | 3/31/14 | 12/31/13 | 9/30/13 | 6/30/13 | ||||||||||||||||
High | $ | 70.74 | $ | 75.94 | $ | 70.03 | $ | 57.50 | $ | 60.49 | $ | 59.42 | $ | 51.61 | $ | 55.99 | |||||||
Low | $ | 62.40 | $ | 59.24 | $ | 52.10 | $ | 50.06 | $ | 53.84 | $ | 50.51 | $ | 46.33 | $ | 46.66 |
3/31/2010 | 3/31/2011 | 3/31/2012 | 3/31/2013 | 3/31/2014 | 3/31/2015 | ||||||||||||
NVE Corporation | $ | 100.00 | $ | 124.37 | $ | 117.00 | $ | 124.55 | $ | 125.92 | $ | 157.06 | |||||
SmallTimes Index | $ | 100.00 | $ | 108.75 | $ | 112.74 | $ | 118.69 | $ | 137.62 | $ | 144.63 | |||||
NASDAQ Industrial Index | $ | 100.00 | $ | 125.60 | $ | 132.43 | $ | 154.07 | $ | 193.10 | $ | 210.26 |
Balance Sheet Data as of March 31 | ||||||||||||||
2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||
Cash, cash equivalents, and marketable securities
|
$ | 100,450,357 | $ | 95,644,701 | $ | 85,260,969 | $ | 73,541,463 | $ | 62,179,707 | ||||
Total assets | $ | 110,089,196 | $ | 105,242,043 | $ | 95,765,496 | $ | 83,126,763 | $ | 71,836,225 | ||||
Total shareholders equity | $ | 108,327,534 | $ | 103,704,641 | $ | 93,984,608 | $ | 81,458,858 | $ | 69,970,549 | ||||
Income Statement Data for Years Ended March 31 |
||||||||||||||
2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||
Revenue | ||||||||||||||
Product sales
|
$ | 29,894,045 | $ | 25,512,028 | $ | 24,434,823 | $ | 25,151,822 | $ | 26,024,823 | ||||
Contract research and development
|
690,043 | 422,879 | 2,598,596 | 3,427,398 | 5,172,240 | |||||||||
Total revenue | $ | 30,584,088 | $ | 25,934,907 | $ | 27,033,419 | $ | 28,579,220 | $ | 31,197,063 | ||||
Gross profit | $ | 24,564,220 | $ | 20,214,630 | $ | 20,008,238 | $ | 19,253,709 | $ | 21,413,365 | ||||
Income from operations | $ | 19,251,951 | $ | 14,393,816 | $ | 15,196,854 | $ | 14,273,048 | $ | 17,669,770 | ||||
Net cash provided by operating activities | $ | 14,870,066 | $ | 12,401,424 | $ | 12,645,302 | $ | 12,811,910 | $ | 12,808,807 | ||||
Net income | $ | 14,368,354 | $ | 11,135,875 | $ | 11,828,838 | $ | 11,381,095 | $ | 13,360,945 | ||||
Net income per share diluted | $ | 2.95 | $ | 2.29 | $ | 2.43 | $ | 2.34 | $ | 2.76 |
Percentage
of Revenue Year Ended March 31 |
Year-to-Year Change Years Ended March 31 |
|||||||||||||
2015 | 2014 | 2013 | 2014 to 2015 | 2013 to 2014 | ||||||||||
Revenue | ||||||||||||||
Product sales
|
97.7 | % | 98.4 | % | 90.4 | % | 17.2 | % | 4.4 | % | ||||
Contract research and development
|
2.3 | % | 1.6 | % | 9.6 | % | 63.2 | % | (83.7 | )% | ||||
Total revenue | 100.0 | % | 100.0 | % | 100.0 | % | 17.9 | % | (4.1 | )% | ||||
Cost of sales | 19.7 | % | 22.1 | % | 26.0 | % | 5.2 | % | (18.6 | )% | ||||
Gross profit | 80.3 | % | 77.9 | % | 74.0 | % | 21.5 | % | 1.0 | % | ||||
Expenses | ||||||||||||||
Selling, general, and administrative
|
7.6 | % | 8.6 | % | 8.3 | % | 3.4 | % | (0.2 | )% | ||||
Research and development
|
9.8 | % | 13.8 | % | 9.5 | % | (16.3 | )% | 39.5 | % | ||||
Total expenses | 17.4 | % | 22.4 | % | 17.8 | % | (8.7 | )% | 21.0 | % | ||||
Income from operations | 62.9 | % | 55.5 | % | 56.2 | % | 33.8 | % | (5.3 | )% | ||||
Interest income | 7.2 | % | 8.2 | % | 8.7 | % | 3.1 | % | (10.1 | )% | ||||
Income before taxes | 70.1 | % | 63.7 | % | 64.9 | % | 29.8 | % | (5.9 | )% | ||||
Income tax provision | 23.1 | % | 20.8 | % | 21.1 | % | 31.4 | % | (6.1 | )% | ||||
Net income | 47.0 | % | 42.9 | % | 43.8 | % | 29.0 | % | (5.9 | )% |
Payments Due by Period | |||||||||||||||
Contractual obligations | Total | <1 Year | 1-3 Years | 3-5 Years | >5 Years | ||||||||||
Operating lease obligations | $ | 1,588,398 | $ | 269,662 | $ | 545,413 |
$ | 559,596 |
$ | 213,727 | |||||
Purchase obligations | 229,050 | 229,050 | - | - | - | ||||||||||
Total | $ | 1,817,448 |
$ | 498,712 |
$ | 545,413 | $ | 559,596 | $ | 213,727 |
Unaudited; Quarter Ended | |||||||||||
March 31, 2015 | Dec. 31, 2014 | Sept. 30, 2014 | June 30, 2014 | ||||||||
Revenue | |||||||||||
Product sales
|
$ | 7,548,468 | $ | 5,883,690 | $ | 8,113,806 | $ | 8,348,081 | |||
Contract research and development
|
23,464 | 408,058 | 153,567 | 104,954 | |||||||
Total revenue | 7,571,932 | 6,291,748 | 8,267,373 | 8,453,035 | |||||||
Cost of sales | 1,378,235 | 1,473,655 | 1,609,632 | 1,558,346 | |||||||
Gross profit | 6,193,697 | 4,818,093 | 6,657,741 | 6,894,689 | |||||||
Expenses | |||||||||||
Selling, general, and administrative
|
523,132 | 533,695 | 625,599 | 629,650 | |||||||
Research and development
|
714,728 | 694,758 | 787,279 | 803,428 | |||||||
Total expenses | 1,237,860 | 1,228,453 | 1,412,878 | 1,433,078 | |||||||
Income from operations | 4,955,837 | 3,589,640 | 5,244,863 | 5,461,611 | |||||||
Income before taxes | 5,474,240 | 4,147,483 | 5,807,786 | 6,010,165 | |||||||
Net income | $ | 3,662,716 | $ | 2,792,906 | $ | 3,875,622 | $ | 4,037,110 | |||
Net income per share diluted | $ | 0.75 | $ | 0.57 | $ | 0.80 | $ | 0.83 | |||
Unaudited; Quarter Ended |
|||||||||||
March 31, 2014 | Dec. 31, 2013 | Sept. 30, 2013 | June 30, 2013 | ||||||||
Revenue | |||||||||||
Product sales
|
$ | 5,857,866 | $ | 6,448,407 | $ | 7,231,149 | $ | 5,974,606 | |||
Contract research and development
|
125,231 | 25,290 | 70,031 | 202,327 | |||||||
Total revenue | 5,983,097 | 6,473,697 | 7,301,180 | 6,176,933 | |||||||
Cost of sales | 1,388,980 | 1,449,396 | 1,503,546 | 1,378,355 | |||||||
Gross profit | 4,594,117 | 5,024,301 | 5,797,634 | 4,798,578 | |||||||
Expenses | |||||||||||
Selling, general, and administrative
|
478,897 | 543,698 | 660,076 | 552,804 | |||||||
Research and development
|
840,719 | 905,246 | 876,463 | 962,911 | |||||||
Total expenses | 1,319,616 | 1,448,944 | 1,536,539 | 1,515,715 | |||||||
Income from operations | 3,274,501 | 3,575,357 | 4,261,095 | 3,282,863 | |||||||
Income before taxes | 3,819,110 | 4,105,740 | 4,781,897 | 3,809,202 | |||||||
Net income | $ | 2,562,225 | $ | 2,777,174 | $ | 3,229,651 | $ | 2,566,825 | |||
Net income per share diluted | $ | 0.53 | $ | 0.57 | $ | 0.66 | $ | 0.53 |
Exhibit # | Description |
3.1 | Amended and Restated Articles of Incorporation of the company as amended by the Board of Directors effective November 21, 2002 (incorporated by reference to the Form 10-QSB for the period ended December 31, 2002). |
3.2 | Bylaws of the company as amended by the Board of Directors effective December 18, 2007 (incorporated by reference to the Form 8-K filed December 19, 2007). |
10.1 | Lease dated October 1, 1998 between the company and Glenborough Properties, LP (incorporated by reference to the Form 10-QSB for the period ended September 30, 2002). |
10.2 | First amendment to lease between the company and Glenborough dated September 18, 2002 (incorporated by reference to the Form 10-QSB for the period ended September 30, 2002). |
10.3 | Second amendment to lease between the company and Glenborough dated December 1, 2003 (incorporated by reference to the Form 10-QSB for the period ended December 31, 2003). |
10.4 | Notification from Carlson Real Estate Company, Inc. relating to change in building ownership (incorporated by reference to the Form 8-K filed October 11, 2005). |
10.5 | Third amendment to lease between the company and Carlson Real Estate (incorporated by reference to the Form 8-K/A filed December 20, 2007). |
10.6 | Letter from Carlson Real Estate relating to transfer of building title (incorporated by reference to the Form 8-K/A filed April 15, 2011). |
10.7 | Fourth amendment to lease between the company and the Barbara C. Gage Revocable Trust (incorporated by reference to our Current Report on Form 8-K/A filed August 3, 2011). |
10.8* | Employment Agreement between the company and Daniel A. Baker dated January 29, 2001 (incorporated by reference to the Form 10-KSB for the year ended March 31, 2001). |
10.9* | NVE Corporation 2000 Stock Option Plan as Amended July 19, 2001 by the shareholders (incorporated by reference to our Registration Statement on Form S-8 filed July 20, 2001). |
10.10+ | Agreement between the company and Agilent Technologies, Inc. dated September 27, 2001 (incorporated by reference to the Form 10-QSB for the period ended September 30, 2001). |
10.11 | Amendment dated October 18, 2002 to Agreement between the company and Agilent (incorporated by reference to the Form 10-QSB for the period ended December 31, 2002). |
10.12 | Report of completion of the divestiture of Agilents Semiconductor Products business (incorporated by reference to the Form 8-K/A filed December 6, 2005). |
10.13+ | Amendment No. 2 to OEM Purchase Agreement between Agilent and the company (incorporated by reference to the Form 8-K/A filed September 11, 2007). |
10.14 | Amendment No. 3 to Agreement between the company and Agilent (incorporated by reference to the Form 8-K/A filed June 28, 2010). |
10.15 | Amendment No. 4 to Agreement between the company and Agilent (incorporated by reference to the Form 8-K/A filed July 1, 2013). |
10.16 | Indemnification Agreement by and between Pacesetter, Inc., a St. Jude Medical Company, d.b.a. St. Jude Medical Cardiac Rhythm Management Division, and the company (incorporated by reference to the Form 8-K filed September 27, 2005). |
10.17+ | Supplier Partnering Agreement by and between St. Jude and the company (incorporated by reference to the Form 8-K filed January 4, 2006). |
10.18+ | Amendment No. 1 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed September 10, 2007). |
10.19+ | Amendment No. 2 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed December 18, 2009). |
10.20+ | Amendment No. 3 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed September 16, 2010). |
10.21 | Amendment No. 4 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed February 7, 2011). |
23.1 | Consent of Grant Thornton LLP. |
23.2 | Consent of Ernst & Young LLP. |
31.1 | Certification by Daniel A. Baker pursuant to Rule 13a-14(a)/15d-14(a). |
31.2 | Certification by Curt A. Reynders pursuant to Rule 13a-14(a)/15d-14(a). |
32 | Certification by Daniel A. Baker and Curt A. Reynders pursuant to 18 U.S.C. Section 1350. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
Name | Title | Date |
/s/Terrence W. Glarner Terrence W. Glarner |
Director and Chairman of the Board |
May 6, 2015 |
/s/Daniel A. Baker Daniel A. Baker |
Director, President & Chief Executive Officer (Principal Executive Officer) |
May 6, 2015 |
/s/Curt A. Reynders Curt A. Reynders |
Treasurer and Chief Financial Officer (Principal Financial and Accounting Officer) |
May 6, 2015 |
/s/Patricia M. Hollister Patricia M. Hollister |
Director | May 6, 2015 |
/s/Richard W. Kramp Richard W. Kramp |
Director | May 6, 2015 |
/s/Gary R. Maharaj Gary R. Maharaj |
Director | May 6, 2015 |
March 31, 2015 | March 31, 2014 | ||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents
|
$ | 9,437,262 | $ | 1,262,300 | |||
Marketable securities, short term
|
20,099,288 | 12,360,091 | |||||
Accounts receivable, net of allowance for uncollectible
accounts of $15,000
|
2,963,974 | 2,331,574 | |||||
Inventories
|
3,742,492 | 3,207,333 | |||||
Deferred tax assets
|
102,052 | 237,387 | |||||
Prepaid expenses and other assets
|
574,913 | 816,276 | |||||
Total current assets | 36,919,981 | 20,214,961 | |||||
Fixed assets | |||||||
Machinery and equipment
|
8,604,926 | 8,536,010 | |||||
Leasehold improvements
|
1,524,298 | 1,499,454 | |||||
10,129,224 | 10,035,464 | ||||||
Less accumulated depreciation
|
7,873,816 | 7,030,692 | |||||
Net fixed assets | 2,255,408 | 3,004,772 | |||||
Marketable securities, long term | 70,913,807 | 82,022,310 | |||||
Total assets | $ | 110,089,196 | $ | 105,242,043 | |||
LIABILITIES AND SHAREHOLDERS EQUITY | |||||||
Current liabilities | |||||||
Accounts payable
|
$ | 358,818 | $ | 374,127 | |||
Accrued payroll and other
|
1,127,136 | 808,675 | |||||
Total current liabilities | 1,485,954 | 1,182,802 | |||||
Long-term deferred tax liabilities | 275,708 | 354,600 | |||||
Shareholders equity | |||||||
Common stock, $0.01 par value,
6,000,000 shares authorized; 4,857,953 issued and outstanding as of March 31,
2015 and 4,851,043 issued and outstanding as of March 31, 2014
|
48,580 | 48,510 | |||||
Additional paid-in capital
|
20,850,762 | 20,464,883 | |||||
Accumulated other comprehensive income
|
746,447 | 877,857 | |||||
Retained earnings
|
86,681,745 | 82,313,391 | |||||
Total shareholders equity | 108,327,534 |
103,704,641 |
|||||
Total liabilities and shareholders equity | $ | 110,089,196 | $ | 105,242,043 |
Year Ended March 31 | |||||||||||
2015 | 2014 | 2013 | |||||||||
Revenue | |||||||||||
Product sales
|
$ | 29,894,045 | $ | 25,512,028 | $ | 24,434,823 | |||||
Contract research and development
|
690,043 | 422,879 | 2,598,596 | ||||||||
Total revenue | 30,584,088 | 25,934,907 | 27,033,419 | ||||||||
Cost of sales | 6,019,868 | 5,720,277 | 7,025,181 | ||||||||
Gross profit | 24,564,220 | 20,214,630 | 20,008,238 | ||||||||
Expenses | |||||||||||
Selling, general, and administrative
|
2,312,076 | 2,235,475 | 2,240,563 | ||||||||
Research and development
|
3,000,193 | 3,585,339 | 2,570,821 | ||||||||
Total expenses | 5,312,269 | 5,820,814 | 4,811,384 | ||||||||
Income from operations | 19,251,951 | 14,393,816 | 15,196,854 | ||||||||
Interest income | 2,187,723 | 2,122,133 | 2,359,603 | ||||||||
Income before taxes | 21,439,674 | 16,515,949 | 17,556,457 | ||||||||
Provision for income taxes | 7,071,320 | 5,380,074 | 5,727,619 | ||||||||
Net income | $ | 14,368,354 | $ | 11,135,875 | $ | 11,828,838 | |||||
Net income per share basic | $ | 2.96 | $ | 2.30 | $ | 2.44 | |||||
Net income per share diluted | $ | 2.95 | $ | 2.29 | $ | 2.43 | |||||
Cash dividends declared per common share | $ | 2.06 | $ | - | $ | - | |||||
Weighted average shares outstanding | |||||||||||
Basic
|
4,855,504 | 4,851,460 | 4,839,810 | ||||||||
Diluted |
4,871,935 | 4,867,691 | 4,863,546 |
Year Ended March 31 | |||||||||||
2015 | 2014 | 2013 | |||||||||
Net income | $ | 14,368,354 | $ | 11,135,875 | $ | 11,828,838 | |||||
Unrealized (loss) gain from marketable securities, net of tax | (131,410 | ) | (679,869 | ) | 470,270 | ||||||
Comprehensive income | $ | 14,236,944 | $ | 10,456,006 | $ | 12,299,108 |
|
Additional Paid-In Capital |
Accumulated Other Comprehen- sive Income (Loss) |
Retained Earnings |
|||||||||||||||||
Common Stock | ||||||||||||||||||||
Shares | Amount | Total | ||||||||||||||||||
Balance at March 31, 2012 | 4,824,745 | $ | 48,247 | $ | 20,974,477 | $ | 1,087,456 | $ | 59,348,678 | $ | 81,458,858 | |||||||||
Exercise of stock
options
|
37,691 | 377 | 143,811 | 144,188 | ||||||||||||||||
Comprehensive income:
|
||||||||||||||||||||
Unrealized gain on
marketable securities,
net of tax |
470,270 | 470,270 | ||||||||||||||||||
Net income
|
11,828,838 | 11,828,838 | ||||||||||||||||||
Total comprehensive income
|
12,299,108 | |||||||||||||||||||
Stock-based compensation
|
66,720 | 66,720 | ||||||||||||||||||
Tax benefit of stock-
based compensation
|
15,734 | 15,734 | ||||||||||||||||||
Balance at March 31, 2013 | 4,862,436 | 48,624 | 21,200,742 | 1,557,726 | 71,177,516 | 93,984,608 | ||||||||||||||
Exercise of stock
options
|
14,000 | 140 | 416,620 | 416,760 | ||||||||||||||||
Repurchase of common stock
|
(25,393 | ) | (254 | ) | (1,263,151 | ) | (1,263,405 | ) | ||||||||||||
Comprehensive income:
|
||||||||||||||||||||
Unrealized loss on
marketable securities,
net of tax |
(679,869 | ) | (679,869 | ) | ||||||||||||||||
Net income
|
11,135,875 | 11,135,875 | ||||||||||||||||||
Total comprehensive income
|
10,456,006 | |||||||||||||||||||
Stock-based compensation
|
53,200 | 53,200 | ||||||||||||||||||
Tax benefit of stock-
based compensation
|
57,472 | 57,472 | ||||||||||||||||||
Balance at March 31, 2014 | 4,851,043 | 48,510 | 20,464,883 | 877,857 | 82,313,391 | 103,704,641 | ||||||||||||||
Exercise of stock
options
|
6,910 | 70 | 302,631 | 302,701 | ||||||||||||||||
Comprehensive income:
|
||||||||||||||||||||
Unrealized loss on
marketable securities,
net of tax |
(131,410 | ) | (131,410 | ) | ||||||||||||||||
Net income
|
14,368,354 | 14,368,354 | ||||||||||||||||||
Total comprehensive income
|
14,236,944 | |||||||||||||||||||
Stock-based compensation
|
58,960 | 58,960 | ||||||||||||||||||
Tax benefit of stock-
based compensation
|
24,288 | 24,288 | ||||||||||||||||||
Cash dividends declared
($2.06 per share of
common stock) |
(10,000,000 | ) | (10,000,000 | ) | ||||||||||||||||
Balance at March 31, 2015 | 4,857,953 | $ | 48,580 | $ | 20,850,762 | $ | 746,447 | $ | 86,681,745 | $ | 108,327,534 |
Year Ended March 31 | |||||||||||
2015 | 2014 | 2013 | |||||||||
OPERATING ACTIVITIES | |||||||||||
Net income | $ | 14,368,354 | $ | 11,135,875 | $ | 11,828,838 | |||||
Adjustments to reconcile net income to net
cash
provided by operating activities:
|
|||||||||||
Depreciation
|
934,371 | 844,339 | 647,163 | ||||||||
Stock-based compensation
|
58,960 | 53,200 | 66,720 | ||||||||
Excess tax benefits
|
(24,288 | ) | (57,472 | ) | (15,734 | ) | |||||
Deferred income taxes
|
155,713 | 121,881 | 51,262 | ||||||||
Changes in operating assets and liabilities
|
|||||||||||
Accounts receivable
|
(632,400 | ) | 189,821 | 163,445 | |||||||
Inventories
|
(535,159 |
) | 129,259 | (107,216 | ) | ||||||
Prepaid expenses and other assets
|
241,363 | 141,871 | 201,705 | ||||||||
Accounts payable and accrued expenses
|
303,152 | (157,350 | ) | (190,881 | ) | ||||||
Net cash provided by operating activities | 14,870,066 | 12,401,424 | 12,645,302 | ||||||||
INVESTING ACTIVITIES | |||||||||||
Purchases of fixed assets | (185,007 | ) | (160,718 | ) | (1,824,324 | ) | |||||
Purchases of marketable securities | (8,997,086 | ) | (22,753,916 | ) | (27,209,753 | ) | |||||
Proceeds from maturities of marketable securities | 12,160,000 | 10,055,000 | 17,194,000 | ||||||||
Net cash provided by (used in) investing activities | 2,977,907 | (12,859,634 | ) | (11,840,077 | ) | ||||||
FINANCING ACTIVITIES | |||||||||||
Proceeds from sale of common stock | 302,701 | 416,760 | 144,188 | ||||||||
Excess tax benefits | 24,288 | 57,472 | 15,734 | ||||||||
Repurchase of common stock | - | (1,263,405 | ) | - | |||||||
Payment of dividends to shareholders | (10,000,000 | ) | - | - | |||||||
Net cash (used in) provided by financing activities | (9,673,011 | ) | (789,173 | ) | 159,922 | ||||||
Increase (decrease) in cash and cash equivalents | 8,174,962 | (1,247,383 | ) | 965,147 | |||||||
Cash and cash equivalents at beginning of year | 1,262,300 | 2,509,683 | 1,544,536 | ||||||||
Cash and cash equivalents at end of year | $ | 9,437,262 | $ | 1,262,300 | $ | 2,509,683 | |||||
Supplemental disclosures of cash flow information: | |||||||||||
Cash paid during the year for income taxes
|
$ | 6,800,000 | $ | 5,263,033 | $ | 5,202,616 |
Year Ended March 31 | |||||
2015 | 2014 | 2013 | |||
Weighted average common shares outstanding basic | 4,855,504 | 4,851,460 | 4,839,810 | ||
Effect of dilutive securities: | |||||
Stock options
|
16,431 | 15,639 | 21,934 | ||
Warrants
|
- | 592 | 1,802 | ||
Shares used in computing net income per share diluted | 4,871,935 | 4,867,691 | 4,863,546 |
Total | <1 Year | 13 Years | 35 Years | |||||||
$ | 91,013,095 | $ | 20,099,288 | $ | 40,220,312 | $ | 30,693,495 |
As of March 31, 2015 | As of March 31, 2014 | ||||||||||||||||||||||||
Adjusted Cost |
Gross Unrealized Gains |
Gross Unrealized Losses |
Fair Market Value |
Adjusted Cost |
Gross Unrealized Gains |
Gross Unrealized Losses |
Fair Market Value |
||||||||||||||||||
Corporate bonds | $ | 88,456,886 |
$ | 1,185,469 | $ | (16,371 | ) | $ | 89,625,984 | $ | 88,567,210 | $ | 1,613,822 | $ | (246,973 | ) | $ | 89,934,059 | |||||||
Municipal bonds | 1,383,839 | 3,272 | - | 1,387,111 | 4,436,430 | 16,521 |
(4,609 | ) | 4,448,342 | ||||||||||||||||
Total | $ | 89,840,725 | $ | 1,188,741 | $ | (16,371 | ) | $ | 91,013,095 | $ | 93,003,640 | $ | 1,630,343 | $ | (251,582 | ) | $ | 94,382,401 |
Less Than 12 Months | 12 Months or Greater | Total | |||||||||||||||||||
Fair Market Value |
Gross Unrealized Losses |
Fair Market Value |
Gross Unrealized Losses |
Fair Market Value |
Gross Unrealized Losses |
||||||||||||||||
As of March 31, 2015 | |||||||||||||||||||||
Corporate bonds | $ | 3,015,900 |
$ | (163 |
) | $ | 2,590,240 | $ | (16,208 |
) | $ | 5,606,140 | $ | (16,371 | ) | ||||||
Municipal bonds | - | - | - | - | - | - | |||||||||||||||
Total | $ | 3,015,900 | $ | (163 | ) | $ | 2,590,240 | $ |
(16,208 |
) | $ | 5,606,140 | $ | (16,371 | ) | ||||||
As of March 31, 2014 | |||||||||||||||||||||
Corporate bonds | $ | 34,761,683 | $ | (246,973 | ) | $ | - | $ | - | $ | 34,761,683 | $ | (246,973 | ) | |||||||
Municipal bonds | 1,418,742 | (4,609 | ) | - | - | 1,418,742 | (4,609 | ) | |||||||||||||
Total | $ | 36,180,425 | $ | (251,582 | ) | $ | - | $ | - | $ | 36,180,425 | $ | (251,582 | ) |
March 31 | |||||
2015 | 2014 | ||||
Raw materials | $ | 738,169 | $ | 776,510 | |
Work in process | 2,302,751 | 1,900,098 | |||
Finished goods | 701,572 | 530,725 | |||
Total inventories | $ | 3,742,492 | $ | 3,207,333 |
Year Ended March 31 | ||||||||
2015 | 2014 | 2013 | ||||||
Risk-free interest rate | 1.6 | % | 1.4 | % | 0.7 | % | ||
Expected volatility | 24 | % | 30 | % | 38 | % | ||
Expected life (years) | 4.2 | 4.3 | 4.1 | |||||
Dividend yield | 0 | % | 0 | % | 0 | % |
Ranges
of Exercise Prices |
Number Outstanding |
Weighted Average Exercise Price |
Weighted Remaining Contractual Life (years) |
||||
$ 15.08 - 16.33 | 18,090 | $ | 16.19 | 0.8 | |||
31.27 - 42.45 | 5,000 | 37.12 | 3.8 | ||||
51.04 - 67.69 | 12,000 | 58.11 | 7.5 | ||||
35,090 | $ | 33.51 | 3.5 |
Option Shares Reserved |
Options Outstanding |
Weighted
Average Option Exercise Price |
Warrants Outstanding |
Weighted
Average Warrant Exercise Price |
||||||||||
At March 31, 2012 | 162,230 | 109,000 | $ | 25.85 | 10,000 | $ | 16.28 | |||||||
Granted
|
(4,000 | ) | 4,000 | $ | 54.11 | - | - | |||||||
Exercised
|
- | (64,000 | ) | $ | 24.23 | - | - | |||||||
Terminated
|
- | - | $ | - | (6,000 | ) | 7.35 | |||||||
At March 31, 2013 | 158,230 | 49,000 | $ | 30.27 | 4,000 | $ | 29.69 | |||||||
Granted
|
(4,000 | ) | 4,000 | $ | 49.86 | - | - | |||||||
Exercised
|
- | (14,000 | ) | $ | 29.77 | - | - | |||||||
Terminated
|
1,000 | (1,000 | ) | $ | 58.27 | (2,000 | ) | 21.99 | ||||||
At March 31, 2014 | 155,230 | 38,000 | $ | 31.78 | 2,000 | $ | 37.38 | |||||||
Granted
|
(4,000 | ) | 4,000 | $ | 67.69 | - | - | |||||||
Exercised
|
- | (6,910 | ) | $ | 43.81 | - | - | |||||||
Terminated
|
- | - | $ | - | (2,000 | ) | 37.38 | |||||||
At March 31, 2015 | 151,230 | 35,090 | $ | 33.51 | - | $ | - |
Year Ended March 31 | |||||||||||
2015 | 2014 | 2013 | |||||||||
Current taxes | |||||||||||
Federal
|
$ | 6,608,923 | $ | 5,010,734 | $ | 5,314,876 | |||||
State
|
330,971 | 304,931 | 377,215 | ||||||||
Deferred taxes | |||||||||||
Federal
|
125,070 | 61,306 | 34,718 | ||||||||
State
|
6,356 | 3,103 | 810 | ||||||||
Income tax provision | $ | 7,071,320 | $ | 5,380,074 | $ | 5,727,619 |
Year Ended March 31 | |||||||||||
2015 | 2014 | 2013 | |||||||||
Tax expense at U.S. statutory rate | $ | 7,503,886 | $ | 5,667,281 | $ | 6,046,264 | |||||
State income taxes, net of Federal benefit | 216,518 | 199,751 | 244,691 | ||||||||
Domestic manufacturing deduction | (600,207 | ) | (443,708 | ) | (460,723 | ) | |||||
Municipal interest | (11,489 | ) | (28,456 | ) | (118,282 | ) | |||||
Other | (37,388 | ) | (14,794 | ) | 15,669 | ||||||
Income tax provision | $ | 7,071,320 | $ | 5,380,074 | $ | 5,727,619 |
March 31 | |||||||
2015 | 2014 | ||||||
Vacation accrual | $ | 114,217 | $ | 137,052 | |||
Inventory reserve | 65,394 | 107,173 | |||||
Depreciation | (63,631 | ) | (37,131 | ) | |||
Stock-based compensation deductions | 107,570 | 120,009 | |||||
Unrealized gain on marketable securities | (425,922 | ) | (500,904 | ) | |||
Other | 28,716 | 56,588 | |||||
Net deferred tax liabilities | $ | (173,656 | ) | $ | (117,213 | ) | |
Reported as: | |||||||
Deferred tax assets
|
$ | 102,052 | $ | 237,387 | |||
Long-term deferred tax liabilities
|
(275,708 | ) | (354,600 | ) | |||
Net deferred tax liabilities | $ | (173,656 |
) | $ | (117,213 | ) |
% of Revenue for Year Ended March 31 | |||||
2015 | 2014 | 2013 | |||
Customer A | 20% | 17% | 14% | ||
Customer B | 16% | 19% | 15% | ||
Customer C | 14% | 15% | 16% | ||
Customer D | 12% | 10% | * |
*Less than 10% |
Year Ended March 31 | ||||||||
2015 | 2014 | 2013 | ||||||
United States | $ | 11,919,548 | $ | 11,159,443 | $ | 12,006,493 | ||
Europe | 13,779,392 | 11,065,547 | 10,666,338 | |||||
Asia | 4,318,209 | 3,374,202 | 3,979,862 | |||||
Other | 566,939 | 335,715 | 380,726 | |||||
Total Revenue | $ | 30,584,088 | $ | 25,934,907 | $ | 27,033,419 |
Year Ending March 31 | |||||||||||||||||||
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Total | |||||||||||||
$ | 269,662 | $ | 270,677 | $ | 274,736 | $ | 277,831 | $ | 281,765 | $ | 213,727 | $ | 1,588,398 |
Exhibit # | Description |
23.1 | Consent of Grant Thornton LLP. |
23.2 | Consent of Ernst & Young LLP. |
31.1 | Certification by Daniel A. Baker pursuant to Rule 13a-14(a)/15d-14(a). |
31.2 | Certification by Curt A. Reynders pursuant to Rule 13a-14(a)/15d-14(a). |
32 | Certification by Daniel A. Baker and Curt A. Reynders pursuant to 18 U.S.C.
Section 1350. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our reports dated May 6, 2015, with respect to the financial statements and internal control over financial reporting included in the Annual Report of NVE Corporation on Form 10-K for the year ended March 31, 2015. We hereby consent to the incorporation by reference of said reports in the Registration Statements of NVE Corporation on Form S-8 (File No. 333-65560).
/s/ Grant Thornton LLP |
Minneapolis, Minnesota |
May 6, 2015 |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the NVE Corporation 2000 Stock Option Plan (as amended by the shareholders on July 19, 2001) and the NVE Corporation 2001 Employee Stock Purchase Plan of our report dated May 1, 2013, with respect to the financial statements of NVE Corporation included in the Annual Report (Form 10-K) of NVE Corporation for the year ended March 31, 2015.
/s/ Ernst & Young LLP |
Minneapolis, Minnesota |
May 6, 2015 |